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Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that orchestrate 
an immune response to variety of pathogens or initiate tolerance. Successful manipulation 
of DCs to control the immune system is a powerful approach for optimizing vaccine 
delivery, tissue engineering, or immunotherapeutic approaches. Biomaterials are widely 
used in combination products for tissue regeneration or vaccine delivery; however 
knowledge of how biomaterials harness DC surface receptors to induce phenotypic 
changes is still lacking, particularly for nanoparticles (NPs). In this study, a point of 
reference is established for the immunogenic effects that gold nanoparticle (AuNP) 
parameters have on DCs. The overall goal of this research is to use this information to 
engineer a specific immune response. Preliminary results indicate a concentration 
dependent relationship between increasing levels of AuNPs and pro-
inflammatory/maturation of DCs for the bare, and Polyethylene glycol (PEG) coated 
nanoparticle treatment groups. AuNPs that were serum coated had the opposite trend, 
where an increasing concentration of AuNPs produced a tolerogenic DC phenotype. 
Additionally, the serum-coated AuNP treatment group showed the highest levels of 
tolerogenic DC expression for all treatment groups, across all concentrations. There 
appears to be no significant difference in the levels of induced mature DC activation 






CHAPTER 1: INTRODUCTION 
NPs have become increasingly investigated in application to vaccine and 
immunotherapy research. There are several benefits to a NP-based approach, including 
targeted delivery of antigen, controlled drug release, improved transport kinetics, tracking 
capability via medical imaging, and multitherapeutric loading [1]. Additionally, NPs can 
be engineered to act as adjuvants themselves, specifically inhibiting or enhancing 
immune responses depending on their variable physical properties.  
One of the most promising applications of NPs in immunotherapy pertains to NP 
interaction with dendritic cells (DCs). However, the potential of NPs to modulate a 
specific immune response through inducing an activated or tolerogenic DC phenotype 
has only been recently explored, and is not well understood.  
The objective of this thesis research was to determine relationships between DC 
phenotype and NP physical properties. The primary hypothesis was that different 
combinations of gold nanoparticle (AuNP) parameters trigger differential DC responses, 
leading to distinct DC activation profiles. Through collaboration with Dr. Warren Chan 
and PhD candidate James Lazarovits at the University of Toronto, AuNP samples of 
distinct size, coating, and concentration were used to study DC phenotype. DC response 
was assessed by maturation marker expression and tolerogenic factor expression using 
fluorescent spectroscopy.   
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CHAPTER 2: RESEARCH SIGNIFICANCE 
Cancer and autoimmune diseases are among the most prevalent diseases in the 
United States and the world. In the United States, over 1.6 million new cases of cancer 
were estimated for 2016, resulting in 500,000 deaths [2]. This year, over 600,000 
Americans are expected to die of cancer, more than 1,650 people a day [3]. Furthermore, 
national expenditure for cancer care totaled nearly $125 billion in 2010, and is projected 
to reach as high as $156 billion in 2020 [2].  
Autoimmune diseases are even more prevalent in the U.S., affecting more than 50 
million Americans, and are the second highest cause of chronic illness in the nation [4]. 
Most autoimmune diseases are debilitating, require a lifetime of treatment and can be 
life-threatening. Because of the high number and variety of prognoses associated with 
autoimmune diseases, a clear national expenditure has been difficult to determine; 
however, in 2001 the National Institutes of Allergy and Infectious Diseases reported 
annual autoimmune disease treatment costs to be greater than $100 billion, and projected 
to increase [4]. 
High morbidity and diagnosis rates for cancer and autoimmune diseases, in 
addition to increasing health care costs are driving the industry to develop cures and more 
effective treatment. One of the greatest hurdles to developing cancer immunotherapies is 
the widespread induced immune tolerance at the tumor site. Antitumor responses elicited 
by the body or current immunotherapy treatments are subdued by the low 
immunogenicity of tumor antigens, proliferation of immunosuppressive cells (e.g. 
regulatory T-cells), and increased production of immunosuppressive cyotkines (IL-10, 
TGF-beta) [5]. An effective antitumor immune response requires the sustained activation 
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and proliferation of tumor-specific effector T-cells. Antigen presenting cells (APCs), 
specifically dendritic cells (DCs), uniquely influence T-cell activity to bridge innate and 
adaptive immunity, making them key cells in generating tumor-specific immunity [6]. 
Therefore, by manipulating DC activity and enhancing the capture of tumor-antigens by 
DCs, a tumor-specific immune response can be actualized. Engineering NPs to target 
DCs, deliver specific antigens, and function as adjuvants themselves could overcome the 
current challenges of cancer immunotherapeutic techniques.  
The defining problem of autoimmune diseases is that the immune system 
responds to self-molecules as if they are foreign entities, attacking the body’s own 
healthy cells and tissues. Immunosuppressant therapies to control this flawed immune 
response are critical for treating autoimmune diseases, such as multiple sclerosis, lupus 
erythematosus, or rheumatoid arthritis [7]. However, immunosuppressant drugs currently 
used are nonspecific, interfere with larger pathways and cells, have toxic effects, and 
increase patient susceptibility to infectious diseases [8, 9]. NPs can potentially ameliorate 
these severe side effects by delivering the optimal amount of immunotherapy to a specific 
site with controlled dosing [7], and through their ability to mediate an immune response 
by manipulating DC activation.  
NPs have already shown promising immunomodulatory effects due to their 
unique physical properties (size, shape, charge, coating etc) which can be engineered to 
optimize biodistribution, site-specific targeting, immunogenicity, and therapeutic loading 
[31]. However, the relationship between different combinations of NP parameters and 
their impact on the immune system is poorly understood.  
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The objective of this research was to gain understanding of how DCs, which are 
central to directing immune responses, integrate signals from multiple stimuli. This 
research is expected to make important contributions to the fields of immunology and 
biomaterials science. Through this research we will gain important insights in rationally 
design the DC environment, particularly using engineered NPs, to direct the DC 
phenotype to influence immune responses in clinical situations such as transplantation, 
cancer and autoimmune disease. 
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CHAPTER 3: LITERATURE REVIEW 
3.1 Innate and Adaptive Immunity 
 The immune system is categorized into two parts, the innate and adaptive responses. 
While there is much interaction between the two responses, they are differentiated based 
on the speed and specificity of the reaction. The innate immune response includes 
physical, chemical, and microbiological barriers, as well as other elements that provide 
an immediate, but non-specific host defense.  Adaptive immunity is more precise, but can 
take several days or weeks to develop. This adaptive response has antigen-specific 
reactions through T lymphocytes and B lymphocytes, and has memory so that subsequent 
exposure has a more rapid and vigorous response [10].  To understand how the innate and 
adaptive immune responses are initiated and linked, it is important to understand the 
biology and function of dendritic cells. 
 
3.2 Dendritic Cells 
Dendritic Cells (DCs) are antigen presenting cells (APCs) that are activated to 
mediate a host immune response. They are integral in both adaptive and innate immunity 
through their role in T cell activation. The principal functions of DCs are to capture and 
present antigens to other cells in the immune system. To accomplish this, DCs 
phagocytize antigens, process them internally, and present the resulting antigen peptide 
on their cell surface. They are found in nearly all tissues and organs, including lymphoid 
organs such as the thymus, spleen and lymph nodes. The activity of DCs in stimulating 
specific T cell responses has shown potential in developing new vaccine strategies for the 
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treatment of a variety of ailments, including infections, allergic and autoimmune diseases, 
and cancer [11]. 
DCs originate from a myeloid progenitor cell in the bone marrow, which can 
differentiate into many cell types, including monocytes. Millions of monocytes are 
produced daily, and normally circulate in the bloodstream for a short time before 
undergoing spontaneous apoptosis [12]. However, during an innate immune response, 
monocytes are recruited to the site of inflammation by chemoattractant proteins that are 
secreted by leukocytes at the site [13]. There they infiltrate into the tissue and 
differentiate into immature dendritic cells (iDCs) when in the presence of granulocyte-
macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) [14]. 
 Initially, chemoattractants resulting from tissue damage, pathogens products, and 
inflammatory cytokines attract iDCs to the site of infection. The iDCs phagocytize 
antigens, degrade them endocytically, and produce antigenic peptides capable of binding 
to major histocompatibility complex class I (MHC I) and MHC II molecules. When these 
surface molecules are synthesized and expressed on the DC surface, the phenotype of the 
cell changes from an iDC to a mature dendritic cell (mDC). The function of the DC also 
changes from antigen capturing cells to antigen presenting cells (APCs). mDCs lose 
responsiveness to inflammatory chemokines, and gain responsiveness to lymphoid 
chemokines, which direct their migration to the draining lymph node [15]. In the lymph 




3.3 T-cell Differentiation  
 For T-cell activation to occur, an immature, or naive T-cell must recognize a foreign 
peptide bound to a MHC molecule while simultaneously receiving a co-stimulatory 
signal from an APC. DCs are one of the few APCs capable of expressing both MHC I 
and MHC II molecules, as well as the co-stimulatory cell-surface molecule necessary for 
the differentiation of T-cells into effector cells and their proliferation. DCs with MHC I 
molecules on their surface stimulate CD8+ T-cells (cytotoxic T-cells), and DCs with 
MHC II molecules stimulate CD4+ T cells (helper T-cells) [15], thus initiating an 
adaptive immune response.  
DCs can also suppress activation of the immune system by inducing the 
differentiation of native T-cells to regulatory T-cells. These tolerogenic DCs (tDCs) have 
low levels of costimulatory molecules, so they provide insufficient stimulatory signals for 
the naive T-cells to differentiate into effector cells. The naïve T-cells instead differentiate 
into regulatory T-cells (Tregs), which downregulate the induction and proliferation of 
effector T-cells, thereby inducing an immunosuppressive response [16].  
Because of the integral role DCs play in the activation of T-cells, inducing a 
particular DC phenotype can induce a corresponding immunoactiving or 
immunosuppressive response. Therefore, finding an effective means of controlling DC 
phenotype is crucial to advancing immunoengineering and immunotherapy based 




Nanoparticles are defined as objects that range in size from 1-100nm. The 
specifications of nanoparticles vary widely, with different sizes, shapes, materials, and 
surface charges possible. Some unique advantages of using nanoparticles in medicine 
include the ability of nanoparticles to function as carriers, target specific tissues or cells, 
control the release of drugs, and exhibit low cell toxicity [17].  
 
3.5 Gold Nanoparticles (AuNPs) 
While Gold (Au) compounds have been used as therapeutic agents for the 
treatment of immune-based diseases for decades, gold nanoparticles (AuNPs) have 
emerged as promising new drugs for immunotherapy treatment. AuNPs are well suited 
for biological applications because of their inertness, water solubility, and nontoxicity. 
They have been used to carry antigens for vaccines and stimulate antigen presentation, 
are actively ingested by phagocytes, and can function as adjuvants [17]. AuNPs have 
been used in gene therapy as well, regulating gene transcript by delivering 
oligonucleotides or small RNA molecules into cells [18]. AuNPs have even been used to 
enhance x-ray imaging and radiotherapy treatment of cancer [19]. 
  Despite these medical advances however, the optimization and adverse effects of 
AuNPs are not well understood, and different studies often yield contradictory results. 
The effects of several variables involving the physiochemical characteristics of 
nanoparticles are poorly described, including size, shape, surface area, coating and 
concentration [20]. Elucidating these properties and their cellular interactions is critical 
for the safe and effective application of AuNPs in nanomedicine.  
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3.6 Application of AuNPs to Immunotherapy 
 Understanding the interaction of NPs with the immune system is critical to optimize 
and develop therapeutic AuNP treatments.  A great deal of research has been done to 
modulate immune responses using DCs, specifically because of their antigen presenting 
capabilities. AuNPs have been studied as potential carriers in application of antigen 
delivery to DCs. Antigens related to viruses and tumors in particular have been studied, 
with results indicating the successful targeted delivery of antigen to DCs through AuNP 
carriers [21, 22]. However, AuNPs do not require the presence of an antigen to have 
immunostimulatory effects on DCs and macrophages [23].  
 
3.6.1 Effect of Nanoparticle Size 
  The size of the NP can influence the efficiency of cellular uptake. NPs that mimic 
pathogens in size and appearance enhance uptake by DCs, which have evolved to 
recognize pathogens of a particular size, such as viruses and bacteria [24]. Studies have 
shown an inverse relationship between the size of the particle and the efficiency of 
particle uptake by DCs [25, 26]. However, it can be difficult to determine an ideal 
particle size because the NPs must be large enough to load if to be used as carriers, but 
particles that are too large are more likely to be eliminated before interacting with DCs. 
Data regarding the impact of NP size on immunological functions has been 
contradictory depending on the specifications of the NPs used in a given experiment. 
Small AuNPs (3 nm in diameter) have been shown to be noncytotoxic and 
nonimmunogenic with macrophages, in that the AuNPs did not elicit the secretion of 
proinflammatory cytokines TNA-alpha and IL1-beta [27]. Non-cytotoxicity has also been 
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shown for DCs and macrophages with lager AuNPs (10 nm and 60 nm in diameter) even 
at high concentrations [28, 29]. However, a contradictory study showed that smaller 
AuNP sizes were associated with increased expression of proinflammatory genes IL-1, 
IL-6 and TNA-alpha, as well as higher cytotoxicity when compared to silver NPs [30]. 
This size-dependent toxicity where smaller AuNPs have greater cytotoxicity has been 
observed in various cell lines [31]. Conflicting results such as these demonstrate the need 
for more optimization studies to clearly understand how particle size affects cellular 
interactions with the NP. 
 
3.6.2 Effect of Nanoparticle Coating  
One method by which NPs can affect an immune response is through the 
phagocytosis of NPs by APCs, including macrophages and DCs. NP coatings can be 
applied to enhance or avoid uptake by APCs, and both results have important 
implications for how effectively a desired immune response can be induced. For example, 
attaching long chain polymers, such as polyethylene glycol (PEG), has been shown to 
decrease phagocytic uptake of NPs, thus prolonging their circulation time [32]. A similar 
decrease in cellular uptake has been shown with serum-coated AuNPs [33]. This result is 
important when targeting NPs to specific tissues or cells, such as for certain cancer 
treatments, where the sequestering of nanoparticles via phagocytosis can cause 
insufficient dosage to the target site. In this case, the ability of NPs to avoid the immune 
system increases their target efficiency.  
  On the other hand, enhanced phagocytosis of NPs is ideal for situations where APCs 
are targeted and utilized to induce a general immune-activating or immunosuppressive 
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response. In this case, NP coatings could be used to enhance phagocytosis, such as the 
facilitation of targeted antigen delivery to DCs by conjugating ligands to the surface of 
NPs for pattern recognition receptors [34]. NPs can also be designed to induce specific 
DC phenotypes (iDC, mDC, or tDC) upon DC phagocytosis of the particles. Through this 
mechanism, NPs can be used to engineer a DC-mediated, specific immune response by 
controlling the differentiation of T-cells into effector or regulatory cells. 
Not only can different coatings give NPs different chemical properties, but 
different densities of the same coating can also cause a change in the affect NPs have. For 
example, a study with using AuNPs and increasing PEG coating densities showed that 
macrophage uptake efficiency was high and serum-dependent at low PEG densities, and 
less efficient and serum-independent at high PEG densities [34].  
Another important implication of selecting a NP coating pertains to the formation 
of an AuNP-protein corona. This dynamic biopolymer layer is important because it forms 
the first nano-bio interface, thus determining how the AuNPs interact with living cells 
[35]. As many as 69 plasma protein can bind to the AuNP surface [36, 37], and these 
proteins largely determine the AuNP’s fate in the body through biodistribution, efficiency 
of cellular uptake and clearance, and immunological properties.  
 
3.6.3 Effect of Nanoparticle Concentration 
The concentration of AuNPs can play a significant role in immunological 
interactions, including cellular uptake, immune activation, and cytotoxicity, but most 
research regarding NP concentration specifically has focused on the potential toxicity of 
AuNPs. Increasing AuNp concentrations have been shown to result in increased rates of 
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acute toxicity and apoptosis, independent of changes in particle size [38, 39]. However, 
the threshold at which concentrations of NPs with particular specifications (size, coating 






CHAPTER 4: DC RESPONSES TO GOLD NANOPARTICLE 
TREATMENTS 
4.1 Materials and Methods 
Methods adapted and modified from Kou PM and Babensee JE. Validation of a 
high-throughput methodology to assess the effects of biomaterials on dendritic cell 
phenotype. Acta Biomaterialia. 6:2621-2630 (2010) [40]. 
4.1.1 Derivation of immature DCs (iDCs) 
Human peripheral blood was collected from consenting volunteers at the Student 
Health Phlebotomy Laboratory in accordance with protocol H10011 or H15072 approved 
by the Institutional Review Board of the Georgia Institute of Technology. The whole 
blood was heparinized (333 U/mL blood) (Abraxis Pharmaceutical Products, 
Schaumburg, IL) and diluted in a 1:1 ratio with phosphate buffered saline (PBS). 
Peripheral blood mononuclear cells (PBMCs) were then isolated by centrifugation using 
lymphocyte separation medium (Cellgro MediaTech, Herndon, VA). Erythrocytes were 
lysed using red blood cell lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM 
EDTA), and after several washing steps using PBS, the PBMCs were resuspended at a 
concentration of 5x106 cells/ml in DC media, comprised of filter-sterilized RMPI-1640 
containing a final concentration of 10% (v/v) heat inactivated fetal bovine serum (Cellgro 
MediaTech, Herndon, VA) and 100 U/ml of Penicillin/Streptomycin (Cellgro 
MediaTech). The cells were then plated in a volume of 10 ml/plate in a tissue-culture dish 
(Primaria 100 x 20 mm2 tissue-culture dish, Becton Dickinson, Franklin Lakes, NJ) and 
incubated for 2 hours at 95% relative humidity and 5% CO2 at 37◦C. Following 
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incubation, the dishes were washed three times with warm DC media to remove non-
adherent cells. New warm media was added to the remaining adherent cells at a volume 
of 10ml/plate, and supplemented with 1000 U/ml GM-CSF and 800 U/ml IL-4 
(PeproTech, Rocky Hill, NJ). The cells were then incubated for a period of 5 days at 95% 
relative humidity and 5% CO2 at 37◦C without changing the media to induce the 
differentiation of monocytes into iDCs. 
 
4.1.2 Human serum extraction  
On day 0 of DC culture, human peripheral blood was collected from consenting 
volunteers at the Student Health Phlebotomy Laboratory in accordance with protocol 
H10011 of H15072 approved by the Institutional Review Board of the Georgia Institute 
of Technology. Blood collected for serum extraction was from the same donor as in 
section 4.2.1. The blood was allowed to clot for 30 minutes at 25◦C, then centrifuged for 
10 minutes at 2000g. The resulting supernatant contained the serum, which was extracted 
and stored at 0◦C for future use on day 5 of DC culture. 
 
4.1.3 AuNP treatments preparation  
Gold nanoparticles (60 nm) were kindly supplied by the University of Toronto 
(Toronto, Canada) as stock solutions containing uncoated (bare), PEG-2K coated and 
PEG-5K coated AuNPs. All stock solutions had an AuNP concentration of 5 nM. The 
bare AuNPs were suspended in ultrapure water and PEGylated AuNPs were suspended in 
PBS in their respective stock solutions. 
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Bare, PEG-2K and PEG-5K coated AuNP treatment preparation 
32 µL of each stock solution were aliquoted; two aliquots of the bare AuNP stock 
were prepared, one for the final bare AuNP treatment and one for the final serum-coated 
AuNP treatment. The four aliquots were centrifuged for 35 minutes at 1200g to pellet the 
AuNPs, then each aliquot was washed twice with sodium citrate tribasic dehydrate 
solution (200 µL, 5 mM), centrifuging samples for 35 minutes at 1200g and aspirating 
the supernatant after each wash. The resulting AuNP pellets of one of the bare AuNP 
aliquots, the PEG-2K AuNP aliquot and the PEG-5K AuNP aliquot were resuspended in 
1 mL RPMI media, for an AuNP treatment sample concentration of 160 pM. A serial 
dilution was performed on these three of the aliquots to obtain three concentrations (160 
pM, 16 pM, and 1.6 pM) for each AuNP coating type.  
 
Serum-coated AuNP treatment preparation  
The pellet in the remaining aliquot of bare AuNPs was resuspended in 40 µL of 
chilled PBS, and added to an Eppendorf tube containing 400 µL of human serum (filtered 
via 0.22 µm PES filter). The AuNPs were incubated in human serum for 1 hour with 95% 
relative humidity and 5% CO2 at 37◦C. After incubation, the serum-AuNP solution was 
centrifuged for 35 min at 1200g and the supernatant was aspirated. The serum-coated 
AuNPs were washed with chilled PBST twice by adding 750 ul chilled PBST, 
centrifuging for 35 min at 1200g, and aspirating the supernatant. After the second PBST 
wash, the serum-coated AuNPs were washed with 1 mL chilled PBS by the same process. 
The final serum-coated AuNP pellet was resuspended in 1 mL RPMI media, for an AuNP 
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treatment sample concentration of 160 pM. A serial dilution was performed to obtain 
three concentrations (160 pM, 16 pM, and 1.6 pM) of serum-coated AuNP solutions.  
 
4.1.4 Treatment of iDCs with AuNPs in 96-well plates 
 On day 5 of DC culture, NP treatments were prepared as described in section 
4.2.3.  Loosely adherent and non-adherent iDCs were harvested and resuspended in DC 
media with 1000 U/ml GM-CSF and 800 U/ml IL-4 at 5x105 DCs/ml. 100 µL of iDCs at 
a concentration of 5 x 105 DCs/ml were plated onto each well in the 96-well tissue culture 
plate (Corning). The wells for the negative control of iDCs remained untreated, the wells 
for the positive control of mDCs were treated with LPS (1 mg/mL; E. coli 055:B5; 
Sigma), and the wells for the positive control of tDCs were treated with human IL-10 
(3,500 U/mL; R&D Systems) and human IFN-alpha (35,000 U/mL; R&D Systems). 150 
μl of each concentration group for each AuNP coating treatment group were added to 
different wells of the 96-well plate containing iDCs, such that the final concentration of 
AuNPs in each well were 0.1 pM, 1.0 pM and 10 pM (Figure 1). The iDCs were then 
incubated with the control, bare AuNP, PEG-2K coated AuNP, PEG-5K coated AuNP, 
and serum coated AuNP treatments for 24 hours with 95% relative humidity and 5% CO2 
at 37◦C. 
 On day 6, the DCs treated in the 96-well plate were transferred directly to wells of 
a 96-well black filter plate wetted with PBS. The supernatants were removed by 
centrifuging the filter plate for 4 minutes at 400rpm. To each well, 100 μl of cold 
working fixation solution (0.05 % paraformaldehyde) was added, and the plate was 
incubated for at least 30 min at room temperature on a microplate shaker at 600 rpm 
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(VWR, West Chester, PA) followed by the removal of the fixative by centrifugation (4 
minutes, 400 rpm). Subsequently, DCs were stained with antibodies for surface marker 
expression, namely, anti-DC-SIGN-FITC (Clone 120507; R & D Systems), anti-CD86-
PE (Clone BU63; Ancell) and anti-ILT3-AF647 (Clone ZM4.1, Biolegend). For isotype 
staining for background fluorescence elimination, the following antibodies were used: 
IgG2B-FITC (clone 133303; R&D Systems), IgG1-PE (clone MOPC31C; Ancell) and 





























Figure 1. Layout of AuNP-DC treatments in 96-well plate. AuNP concentrations of 0.1 pM, 1.0 pM 
and 10 pM were added to DCs in individual wells for all AuNP treatment groups (bare, serum 
coated, PEG-2K coated, and PEG-5K coated AuNPs). Antibody staining was added to three of the six 
wells used for each treatment, and isotype staining was added to the other three wells.  
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The plate was incubated in a plate shaker (600 rpm) at 40ºC for 40 minutes 
protected from light. After this staining procedure, DCs were washed three times with 
washing solution of 0.1% BSA and 2mM EDTA in PBS, pH 7.20 by centrifugation at 
400 RCF for 4 min. Afterwards, 100 μl of the washing solution was added to DCs and the 
fluorescence of each treatment group were measured. The geometric mean fluorescent 
intensities were measured with a Tecan Infinite F500 microplate reader (Tecan US, 
Durham, NC) using excitation filters of 535/25 and 485/20 and the emission filters of 
590/20 and 535/25, for PE and FITC, respectively, and 650/668 for anti-ILT3 - AF647.  
 The surface marker, CD86, is a costimulatory molecule for which expression 
becomes up-regulated upon DCs maturation. Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) is an endocytic receptor which 
expression is not significantly down-regulated upon DCs maturation. Immunoglobulin-
like transcript 3 (ILT3) is an inhibitory receptors which expression is up-regulated upon 
anti-inflammatory (tolerogenic) DC response. The ratio of respective geometric mean 
fluorescent intensities for CD86 expression divided by DC-SIGN expression defines the 
metric of “inflammatory maturation factor” (IMF) as an indicator of pro-inflammatory 
DC phenotype. The ratio of respective geometric mean fluorescent intensities for ILT3 
expression divided by CD86 expression defines the metric of “tolerogenic maturation 
factor” (TMF) as an indicator of tDC phenotype. 
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4.2. Results  
4.2.1 DCs treated with serum coated AuNPs had the greatest tolerogenic maturation 
factor expression 
The TMF, as defined by the ratio of the geometric mean fluorescent intensities for 
ILT3/CD86, was determined for each AuNP coating type and concentration. As expected, 
the DCs treated with IL-10 and IFN-alpha to act as the positive tDC control had a 
significantly higher TMF than both the iDC and mDC controls, and the mDC control had 
a very low TMF (Figure 2). The TMF for the tDC control was higher than DCs treated 
with any concentration of bare, PEG-2K, or PEG-5K coated AuNPs. However, all 
concentrations of the serum-coated AuNP treatments showed a higher TMF than any 
other treatment group, including the tDC control. The PEG-5K coated AuNP treatment 
group of DCs had TMFs that were lower than the iDC control for AuNP concentrations 
0.1 pM and 10 pM; at 1 pM, the TMF was higher than that of the iDC control. The bare 
AuNP treatment, serum coated AuNP treatment, and PEG-2K treatment showed a slight 
concentration dependence with increasing concentrations of AuNPs and an increased 
TMF (Figure 2).  
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Figure 2. Tolerogenic maturation factor (ILT3/CD86) of DCs treated with AuNPs with mean ± 
range, n=2 donors. Treatments of different AuNP coatings (bare, serum, PEG-2K, PEG-5K) and 
concentrations (0.1 pM, 1.0 pM, 10 pM) were used. DCs were incubated with AuNP treatments for 24 
hours at 37°C. DCs were stained with antibodies for surface marker expression, stained with isotype 
for background and geometric mean fluorescent intensities were determined for ILT3 and CD86 
expression for each treatment group using a Tecan Infinite F500 microplate reader. 
 
4.2.2 Inflammatory maturation factor expression showed concentration dependence 
for DCs treated with bare AuNPs and serum-coated AuNPs 
The IMF, as defined by the ratio of the geometric mean fluorescent intensities for 
CD86/DCSIGN, was determined for each AuNP coating type and concentration. As 
expected, the positive control for inflammatory DC maturation (mDC) had the highest 
IMF, and the positive control for tolerogenic DC maturation (tDC) had the lowest IMF. 
DCs treated with the bare AuNP treatment group showed a strong positive correlation 
with increasing bare AuNP concentration and an increased IMF. The reverse trend was 
seen with the serum coated AuNP treatment group, where increasing concentrations of 
serum coated AuNPs were correlated to a decrease in the IMF (Figure 3). This apparent 
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concentration dependence for the serum coated AuNPs was seen with the TMF as well, 
with increasing concentrations of AuNPs correlating to an increased TMF (Figure 2).  
 
Figure 3. Inflammatory maturation factor (CD86/DCSIGN) of DCs treated with AuNPs with mean ± 
range, n=2 donors. Treatments of different AuNP coatings (bare, serum, PEG-2K, PEG-5K) and 
concentrations (0.1 pM, 1.0 pM, 10 pM) were used. DCs were incubated with AuNP treatments for 24 
hours at 37°C. DCs were stained with antibodies for surface marker expression, stained with isotype 
for background and geometric mean fluorescent intensities were determined for CD86 and DCSIGN 
expression for each treatment group using a Tecan Infinite F500 microplate reader. 
4.3 Discussion 
The phenotype of DCs was differentially modulated by bare, serum-coated, PEG-
2K coated, and PEG-5K coated AuNPs. Specifically, serum coated AuNPs had the 
highest levels of TMF (ILT3/CD86) for all concentration groups (0.1 pM, 1.0 pM, 10 
pM), and all concentrations of serum coated AuNPs were also higher than the TMF for 
the tDC control. Additionally, the serum coated AuNPs showed concentration 
dependence for both the TMF and IMF values; increasing the concentrations of serum 
coated AuNPs increased the TMF and decreased the IMF. This indicates that the 
interaction between serum coated AuNPs and DCs resulted in greater levels of ILT3 
expression on the DCs and a tolerogenic phenotype. The bare AuNPs also showed a 
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concentration dependent effect but for IMF expression, where increasing bare AuNP 
concentrations showed an increased IMF. However, the IMFs for all bare AuNP 
concentrations were still lower than the positive control, mDC. These results indicate that 
in the presence of bare AuNPs, DC expression of CD86 increases, therefore causing an 
inflammatory, activated DC phenotype.  
The PEG-5K treatment group did not show concentration dependence for TMF, 
and the TMF values of all concentrations were closest to the iDC control. While 
concentration dependence was seen for PEG-5K coated AuNPs for IMF levels, these 
values were also closer to the iDC control than tDCs or mDCs. The PEG-2K coated 
AuNP treatment stayed within a similar range of TMFs and IMFs as the PEG-5K coated 
AuNP group. However, a slight concentration dependence was shown for the PEG-2K 
AuNP treatment for TMF, but not for IMF. These results indicate that the PEG-2K and 
PEG-5K AuNP coatings did not show a significant change in DC phenotype towards an 
activating or tolerogenic phenotype.  
It is important to note that this data was accumulated from only two donors. More 
trials are necessary to demonstrate the statistical significance of the trends observed in 
these preliminary results for bare and serum coated AuNPs, as well as to demonstrate that 
the PEGylated AuNPs did not have a significant effect on DC phenotype. Additionally, 
an assumption being made in the analysis of the data in this study is that the AuNPs are 
actually being phagocytized by the DCs, which may not necessarily be the case. Because 
this is an in vitro study, DCs may simply be interacting with serum molecules and NPs in 
solution because there is not a complicated matrix of additional molecules and cells that 
would be found in vivo. In subsequent studies, the uptake of NPs by DCs should be 
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measured using Inductively Coupled Plasma-Atomic Emissions Spectroscopy (ICP-AES) 
for gold and magnesium content. DC responses to NPs will also be further characterized 
by cytokine profile analysis using Mulliplex bead technology. 
 
5 Conclusion and Future Work 
 The data in this study indicates a strong tolerogenic inducing effect for DCs 
treated with serum-coated AuNPs, concentration dependence for an increased tolerogenic 
phenotype with increasing concentrations of serum coated AuNPs, and concentration 
dependence for an increased inflammatory phenotype with increasing concentrations of 
bare AuNPs. Additional experimental runs to increase donor number are needed to show 
statistical significance for the preliminary results shown here.  
 Future work should include examination of NP treatment variables such as using a 
greater range of concentrations to explore the extent of apparent concentration 
dependence (0.1pM – 100pM), using different sizes of AuNPs to assess the impact that 
NP size has on DC phenotypic changes (15nm, 60nm, 100nm), and testing a range of 
DC-AuNP exposure times (1 hour, 12 hours, 24 hours). Additionally, subsequent studies 
should be performed to further study the effect that AuNPs have on DCs and mechanism 
by which AuNPs alter DC phenotype, including cytotoxicity analysis using Vybrant 
Cytotoxicity Assay (Molecular Prodes, Eugene, OR), cytokine profile analysis using 
Mulliplex bead technology, and DC imaging to assess the extent of AuNP internalization 
using Inductively Coupled Plasma-Atomic Emissions Spectroscopy (ICP-AES) for gold 
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